This pattern is in accordance with other studies where MGMT promoter is reported methylated in 30–60% of GBM31 and in 30–90% of low-grade gliomas including Astrocytoma and Oligidendrioglioma13,17,21. This evidence concerns the gene MGMT and central nervous system cancer.